Field evaluation of marbofloxacin 10 percent injectable solution in the treatment of metritis - mastitis - agalactia (MMA) syndrome in sows

摘要

Metritis-Mastitis-Agalactia (MMA) syndrome in sows is a major problem: it can lead to increased mortality of the piglets before weaning, increased susceptibility lo infectious agents and low growth rate of the surviving piglets. Pathogenesis can beexplained by the action of endoloxins from Gram negative bacteria - particularly Escherichia coli - harboured in the udder, the genito-urinary tract or the intestine, on immune, cardio-vascular and endocrine systems. Treatment of this syndrome requires the use of anti-infectious agents to eliminate bacteria from the infected organ(s). Marbofloxacin is of interest in the treatment of MMA syndrome, due to its broad spectrum of bactericidal activity particularly against Enterobacteriaceae, whose minimum inhibitory concentration (MIC) values are generally lower than 0.05 mu g/ml. In addition, marbofloxacin has a high volume of distribution, characterising very good tissue diffusion. At the usual dose of 2 mg/kg in the lactating sow, concentrations achievedin urine and in milk are high and generally well above MIC values for the main pathogens involved in MMA syndrome.